HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies
Karen Schreiber(Guy's and St Thomas' NHS Foundation Trust), Beverley J. Hunt, Susan Robinson(Guy's and St Thomas' NHS Foundation Trust), Dario Roccatello(Ospedale San Giovanni Bosco), Savino Sciascia, Paul T. Seed(St Thomas' Hospital), Karen Breen(University College London Hospitals NHS Foundation Trust), Hannah Cohen(University College Hospital), Søren Jacobsen(Copenhagen University Hospital), Linda Watkins(University of Liverpool), Saskia Middeldorp(Amsterdam UMC Location University of Amsterdam), Lesley Regan(St Mary's Hospital), Sue Pavord(University of Oxford)
Cited by 125
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
ESHRE guideline: recurrent pregnancy loss
|Human Reproduction Open|2018|993
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
|New England Journal of Medicine|2019|945
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|861